CAR-T Cell Engineering

Lesson 1 • T Cell Immunology Essentials

Covers T cell development, activation, and effector functions. Provides the immunological baseline required for understanding CAR-mediated signaling.

Lesson 2 • Tumor Immunology and Immune Evasion

Examines how tumors evade immune surveillance and why conventional T cells fail. Contextualizes the therapeutic need for engineered CAR-T cells.

Lesson 3 • History and Clinical Rationale of CAR-T

Traces the evolution from early adoptive transfer to approved CAR-T products. Frames clinical milestones that shaped current engineering standards.

Lesson 1 • Safety Switch and Controllable CAR Systems

Introduces suicide genes, ON/OFF switches, and logic-gated CARs for safety control. Addresses regulatory and clinical requirements for controllable CAR expression.

Lesson 2 • Hinge and Transmembrane Domain Engineering

Examines how hinge length and transmembrane sequences affect CAR flexibility and signaling. Guides domain selection for optimal synapse formation.

Lesson 3 • Intracellular Signaling Domain Design

Details CD3ζ signaling and co-stimulatory domain combinations across CAR generations. Connects signaling architecture to persistence, exhaustion, and cytokine profiles.

Lesson 4 • CAR Generation Comparison and Selection

Compares first- through fourth-generation CARs across efficacy and safety metrics. Enables evidence-based selection of CAR architecture for a given indication.

Lesson 1 • T Cell Activation Protocols

Covers anti-CD3/CD28 bead and soluble stimulation methods for T cell activation. Activation quality directly determines transduction efficiency and product potency.

Lesson 2 • Cytokine Supplementation and Culture Conditions

Examines IL-2, IL-7, IL-15, and IL-21 roles in T cell expansion and phenotype. Cytokine choice shapes memory subset composition and in vivo persistence.

Lesson 3 • Autologous vs. Allogeneic T Cell Sources

Compares patient-derived and donor-derived T cell platforms across efficacy and logistics. Frames the manufacturing and clinical trade-offs of each approach.

Lesson 4 • Leukapheresis and T Cell Enrichment

Details apheresis procedures, mononuclear cell isolation, and T cell subset enrichment. Connects starting material quality to downstream manufacturing success.

Lesson 1 • Retroviral Vector Platforms

Examines gamma-retroviral vectors, their integration preferences, and clinical history. Contrasts with lentiviral systems to guide platform selection.

Lesson 2 • Transgene Expression Optimization

Addresses promoter selection, codon optimization, and post-transcriptional elements. Ensures stable, high-level CAR expression without silencing or toxicity.

Lesson 3 • Lentiviral Vector Production and Use

Covers lentiviral packaging, pseudotyping, and transduction protocols. Establishes lentiviral delivery as the current clinical standard for stable CAR integration.

Lesson 4 • Site-Specific Integration Strategies

Covers CRISPR-mediated knock-in and safe harbor loci for precise CAR insertion. Connects targeted integration to consistent expression and reduced genotoxicity.

Lesson 1 • Transduction and Expansion Workflow

Details the sequential steps from vector addition through large-scale T cell expansion. Connects process parameters to transduction efficiency and cell yield.

Lesson 2 • Process Development and Scale-Up

Examines process characterization, scale-up challenges, and tech transfer principles. Prepares students to translate bench processes to clinical manufacturing scale.

Lesson 3 • Manufacturing Platform Overview

Introduces closed-system bioreactors, G-Rex flasks, and automated platforms. Establishes the manufacturing landscape and scalability considerations for clinical production.

Lesson 4 • Harvest, Formulation, and Cryopreservation

Addresses cell washing, concentration, cryoprotectant addition, and controlled-rate freezing. Final formulation steps directly affect product viability and clinical shelf life.

Lesson 1 • Pharmacokinetics and Biodistribution

Covers CAR-T cell trafficking, tissue distribution, and persistence measurement methods. PK/PD data informs dosing strategy and supports regulatory safety narratives.

Lesson 2 • In Vitro Efficacy Models

Covers co-culture cytotoxicity assays, 3D tumor spheroid models, and antigen titration. In vitro data establishes proof-of-concept and informs dose-ranging for in vivo studies.

Lesson 3 • Toxicology and Safety Studies

Addresses on-target off-tumor toxicity, cytokine release syndrome models, and genotoxicity. Safety data packages must satisfy regulatory requirements for first-in-human studies.

Lesson 4 • Translational Bridging to Clinical Design

Connects preclinical findings to first-in-human dose selection and trial design. Ensures preclinical data packages are structured to support IND submission.

Lesson 1 • Release Testing Panel Design

Defines identity, purity, potency, and safety tests required for product release. Links each assay to a specific quality attribute and regulatory expectation.

Lesson 2 • Regulatory Pathways for Advanced Therapies

Navigates IND, BLA, and advanced therapy regulatory designations for CAR-T products. Prepares students to structure regulatory submissions and interact with health authorities.

Lesson 3 • GMP Facility and Documentation Requirements

Examines cleanroom classification, environmental monitoring, and batch record systems. GMP compliance is the operational foundation for regulatory approval and patient safety.

Lesson 4 • Potency Assay Development

Covers cytotoxicity, cytokine release, and proliferation assays as potency measures. Potency assays must correlate with clinical mechanism of action for regulatory acceptance.

Lesson 1 • Managing CAR-T Toxicities

Addresses cytokine release syndrome, neurotoxicity, and prolonged cytopenias management. Clinical toxicity management directly affects patient safety and product development strategy.

Lesson 2 • Next-Generation CAR Engineering Approaches

Surveys armored CARs, TRUCKs, universal CARs, and in vivo CAR delivery. Positions students to evaluate and contribute to the leading edge of CAR-T innovation.

Lesson 3 • Clinical Trial Design for CAR-T

Covers phase I dose escalation, response endpoints, and patient selection criteria. Connects trial design choices to regulatory requirements and scientific objectives.

Lesson 4 • Resistance Mechanisms and Relapse

Examines antigen loss, T cell exhaustion, and tumor microenvironment-driven resistance. Understanding resistance informs next-generation CAR design and combination strategies.